AuctuCel
Spin-off from A*STAR's Bioprocessing Technology Institute that launched in August 2025 with Fluxperior, an AI-powered platform that models cell nutrition and metabolism to design culture-media formulations; the company reports cutting the cost and time of developing media for cell therapies and other cell-based medicines by up to 80%.
Headquarters
Singapore
Year Founded
2024
Founders
Fhu Chee Wai (co-founder and CEO), Zach Pang (co-founder)
Country
Singapore
Financial Information
Funding Stage
Grant (Startup SG)
Recent Funding
$50K
Funding By
Enterprise Singapore (Startup SG)
Core Technology
AI-driven computational modelling of cell nutrition and metabolism (Fluxperior)
Product Type
AI Platform
Pipeline Stage (Very Important)
Regulatory Status
- IND Filed: N/A
- FDA/EMA Status: N/A
- Clinical Trial Registration: N/A
- Patents / IP Status: Not disclosed
Partnerships
Pharma Collaborations
None disclosed
Academic / Hospital Tie-ups
A*STAR Bioprocessing Technology Institute (spin-off origin)
CRO/CDMO Partnerships
None disclosed
Market & Differentiation
Cuts cell-culture media development cost and time by up to 80% for cell-based medicines